Guggenheim Lowers Intellia Therapeutics (NASDAQ:NTLA) Price Target to $45.00

Intellia Therapeutics (NASDAQ:NTLA) had its price target reduced by equities researchers at Guggenheim from $55.00 to $45.00 in a research report issued on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Guggenheim’s price target would indicate a potential upside of 416.11% from the stock’s previous close.

Several other research analysts have also commented on the stock. StockNews.com upgraded shares of Intellia Therapeutics to a “sell” rating in a research note on Monday, March 3rd. Chardan Capital reissued a “buy” rating and set a $68.00 target price on shares of Intellia Therapeutics in a research report on Friday. Oppenheimer dropped their target price on shares of Intellia Therapeutics from $60.00 to $40.00 and set an “outperform” rating on the stock in a research report on Monday, January 13th. Wells Fargo & Company dropped their target price on shares of Intellia Therapeutics from $60.00 to $50.00 and set an “overweight” rating on the stock in a research report on Friday, February 28th. Finally, JPMorgan Chase & Co. restated a “neutral” rating and set a $13.00 price objective (down from $45.00) on shares of Intellia Therapeutics in a research note on Friday, February 28th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $36.90.

Intellia Therapeutics Price Performance

NASDAQ NTLA traded up $0.60 during trading on Monday, reaching $8.72. 470,406 shares of the company’s stock traded hands, compared to its average volume of 3,374,604. The firm has a market cap of $903.14 million, a price-to-earnings ratio of -1.60 and a beta of 2.33. The company’s 50 day simple moving average is $8.13 and its two-hundred day simple moving average is $10.97. Intellia Therapeutics has a 12-month low of $5.90 and a 12-month high of $28.18.

Intellia Therapeutics (NASDAQ:NTLA) last posted its earnings results on Thursday, May 8th. The company reported ($1.10) EPS for the quarter, beating analysts’ consensus estimates of ($1.26) by $0.16. The business had revenue of $16.63 million for the quarter, compared to analysts’ expectations of $11.39 million. The company’s revenue for the quarter was down 42.6% on a year-over-year basis. During the same period last year, the business posted ($1.12) EPS. Research analysts expect that Intellia Therapeutics will post -5.07 earnings per share for the current fiscal year.

Institutional Trading of Intellia Therapeutics

Several large investors have recently made changes to their positions in NTLA. Barclays PLC raised its position in shares of Intellia Therapeutics by 17.7% in the third quarter. Barclays PLC now owns 292,795 shares of the company’s stock valued at $6,017,000 after buying an additional 44,022 shares during the last quarter. Green Alpha Advisors LLC acquired a new stake in shares of Intellia Therapeutics during the fourth quarter valued at about $138,000. AdvisorNet Financial Inc increased its position in shares of Intellia Therapeutics by 96.4% during the fourth quarter. AdvisorNet Financial Inc now owns 10,085 shares of the company’s stock valued at $118,000 after acquiring an additional 4,950 shares during the last quarter. Signal Advisors Wealth LLC increased its position in shares of Intellia Therapeutics by 59.9% during the fourth quarter. Signal Advisors Wealth LLC now owns 74,158 shares of the company’s stock valued at $865,000 after acquiring an additional 27,782 shares during the last quarter. Finally, Hennion & Walsh Asset Management Inc. increased its position in shares of Intellia Therapeutics by 125.2% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 120,997 shares of the company’s stock valued at $1,411,000 after acquiring an additional 67,276 shares during the last quarter. 88.77% of the stock is currently owned by hedge funds and other institutional investors.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.